Plus Therapeutics (PSTV) Set to Announce Quarterly Earnings on Thursday

Plus Therapeutics (NASDAQ:PSTV) is set to release its earnings data after the market closes on Thursday, November 14th. Analysts expect Plus Therapeutics to post earnings of ($0.46) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Plus Therapeutics (NASDAQ:PSTV) last posted its earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share for the quarter. The firm had revenue of $1.28 million for the quarter. On average, analysts expect Plus Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Plus Therapeutics Stock Up 8.4 %

Shares of Plus Therapeutics stock opened at $1.29 on Wednesday. Plus Therapeutics has a 12-month low of $1.15 and a 12-month high of $2.78. The stock has a market capitalization of $7.61 million, a P/E ratio of -0.42 and a beta of 0.69. The company has a 50-day simple moving average of $1.41 and a 200 day simple moving average of $1.68.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on PSTV shares. Ascendiant Capital Markets cut their target price on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Plus Therapeutics in a research report on Friday, August 16th.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.